Effects of Systemic and Local Administration of Recombinant Human IGF-I (rhIGF-I) on De Novo Bone Formation in an Aged Mouse Model

Fowlkes, John L.; Thrailkill, Kathryn M.; Liu, Lichu; Wahl, Elizabeth C.; Bunn, R. Clay; Cockrell, Gael; Perrien, Daniel S.; Aronson, James; Lumpkin, Charles K.

doi:10.1359/jbmr.060618

Cited by 63 publications

(42 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistently, reduction in serum IGF1 levels results in decreased subperiosteal expansion and bone strength (105). In vivo treatment with IGF1 stimulates bone formation (106). However, IGF1 administration only partially restores the deficit in the expression of osteoblast markers in aging animals (107), possibly because aging induces receptormediated skeletal resistance to IGF1 (108).…”

Section: Growth Factorsmentioning

confidence: 99%

Osteoblasts in osteoporosis: past, emerging, and future anabolic targets

Marie¹,

Kassem²

2011

European Journal of Endocrinology

187

143

View full text Add to dashboard Cite

Objective: Age-related bone loss is associated with significant changes in bone remodeling characterized by decreased trabecular and periosteal bone formation relative to bone resorption, resulting in bone fragility and increased risk of fractures. Prevention or reversal of age-related decrease in bone mass and increase in bone fragility has been based on inhibition of bone resorption using anticatabolic drugs. The current challenge is to promote osteoblastogenesis and bone formation to prevent age-related bone deterioration. Methods: A limited number of approved therapeutic molecules are available to activate bone formation. Therefore, there is a need for anabolic drugs that promote bone matrix apposition at the endosteal, endocortical, and periosteal envelopes by increasing the number of osteoblast precursor cells and/or the function of mature osteoblasts. In this study, we review current therapeutics promoting bone formation and anabolic molecules targeting signaling pathways involved in osteoblastogenesis, based on selected full-text articles searched on Medline search from 1990 to 2010. Results and discussion: We present current therapeutic approaches focused on intermittent parathyroid hormone and Wnt signaling agonists/antagonists. We also discuss novel approaches for prevention and treatment of defective bone formation and bone loss associated with aging and osteoporosis. These strategies targeting osteoblastic cell functions may prove to be useful in promoting bone formation and improving bone strength in the aging population.

show abstract

Section: Growth Factorsmentioning

confidence: 99%

Osteoblasts in osteoporosis: past, emerging, and future anabolic targets

Marie¹,

Kassem²

2011

European Journal of Endocrinology

187

143

View full text Add to dashboard Cite

show abstract

“…In muscle, mRNA levels of both isoforms, IGF-I Ea and MGF, are upregulated by mechanical loading (27). The anabolic effects of IGF-I Ea and MGF on bone are less well characterized (19). In bone, MGF E-peptide (a 23-amino acid peptide encoded the MGF E-domain) stimulates osteoblast proliferation, whereas IGF-I Ea stimulates both osteoblast proliferation and differentiation (15,40).…”

Section: E391 Muscle Anabolic and Metabolic Factors In Osteocytesmentioning

confidence: 99%

Expression of muscle anabolic and metabolic factors in mechanically loaded MLO-Y4 osteocytes

Juffer

Jaspers²,

Lips

et al. 2012

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…79 Consequently, localized IGF delivery was explored and showed to enhance bone formation without increasing circulating IGF-I levels. 80,81 Although insulin can bind to the IGF receptor as well, higher concentrations will be required due to its lower affinity. Since this may cause hypoglycaemia, insulin will probably never be considered as a therapeutic agent for bone regeneration.…”

Section: Insulin-like Growth Factormentioning

confidence: 99%

Growth Factor Interactions in Bone Regeneration

Kempen

Creemers

Alblas

et al. 2010

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Bone regeneration is a complex process regulated by a large number of bioactive molecules. Many growth factors and cytokines involved in the natural process of bone healing have been identified and tested as potential therapeutic candidates to enhance the regeneration process. Although many of these studies show an enhancement of the bone regeneration process by a single drug therapy, in vivo bone regeneration is the result of a complex interplay between the applied growth factor and various endogenous produced growth factors. To investigate these growth factor interactions, various studies have investigated the effect of growth factor combinations on bone regeneration. This review provides an overview of the growth factor and cytokine combinations tested in translational bone regeneration studies and shows that their interaction may result in an enhancement or inhibition of bone formation.

show abstract

Effects of Systemic and Local Administration of Recombinant Human IGF-I (rhIGF-I) on De Novo Bone Formation in an Aged Mouse Model

Cited by 63 publications

References 71 publications

Osteoblasts in osteoporosis: past, emerging, and future anabolic targets

Osteoblasts in osteoporosis: past, emerging, and future anabolic targets

Expression of muscle anabolic and metabolic factors in mechanically loaded MLO-Y4 osteocytes

Growth Factor Interactions in Bone Regeneration

Contact Info

Product

Resources

About